{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:53:09Z","timestamp":1794808389374,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53220-6","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:51:44Z","timestamp":1735555904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Mark N.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-0536","authenticated-orcid":false,"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-6212","authenticated-orcid":false,"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama S.","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-3159","authenticated-orcid":false,"given":"Martin E.","family":"Guiterrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":false,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-7732","authenticated-orcid":false,"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line F.","family":"Jacquemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Senesac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-2499","authenticated-orcid":false,"given":"J. Henri","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity D.","family":"Scripture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica S.","family":"Chatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"53220_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"YJ Chen","year":"2023","unstructured":"Chen, Y. J., Abila, B. & Mostafa Kamel, Y. CAR-T: what is next? Cancers 15, 663 (2023).","journal-title":"Cancers"},{"key":"53220_CR2","doi-asserted-by":"publisher","first-page":"438.e431","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant. Cell. Ther. 29, 438.e431\u2013438.e416 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"53220_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. & Rodriguez, A. CAR-T therapies in solid tumors: opportunities and challenges. Curr. Oncol. Rep. 25, 479\u2013489 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"53220_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"53220_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI44327","volume":"121","author":"P Narayanan","year":"2011","unstructured":"Narayanan, P. et al. A composite MyD88\/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J. Clin. Investig. 121, 1524\u20131534 (2011).","journal-title":"J. Clin. Investig."},{"key":"53220_CR6","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.95.18.10437","volume":"95","author":"T Clackson","year":"1998","unstructured":"Clackson, T. et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. USA 95, 10437\u201310442 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53220_CR7","doi-asserted-by":"crossref","unstructured":"Foster, A. E. et al. Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88\/CD40. Mol. Ther. 25, 2176\u20132188 (2017).","DOI":"10.1016\/j.ymthe.2017.06.014"},{"key":"53220_CR8","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata, M. et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 7, 1306\u20131319 (2017).","journal-title":"Cancer Discov."},{"key":"53220_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.omto.2018.12.009","volume":"12","author":"MT Duong","year":"2019","unstructured":"Duong, M. T. et al. Two-dimensional regulation of CAR-T cell therapy with orthogonal switches. Mol. Ther. Oncolytics 12, 124\u2013137 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"53220_CR10","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","volume":"95","author":"RE Reiter","year":"1998","unstructured":"Reiter, R. E. et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95, 1735\u20131740 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53220_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1006\/bbrc.2000.3393","volume":"275","author":"G Bahrenberg","year":"2000","unstructured":"Bahrenberg, G., Brauers, A., Joost, H. G. & Jakse, G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun. 275, 783\u2013788 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"53220_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ijc.10903","volume":"103","author":"AG de Nooij-van Dalen","year":"2003","unstructured":"de Nooij-van Dalen, A. G. et al. Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int. J. Cancer 103, 768\u2013774 (2003).","journal-title":"Int. J. Cancer"},{"key":"53220_CR13","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.3390\/s120505461","volume":"12","author":"Y Ruan","year":"2012","unstructured":"Ruan, Y., Yu, W., Cheng, F., Zhang, X. & Larr\u00e9, S. Detection of prostate stem cell antigen expression in human prostate cancer using quantum-dot-based technology. Sensors 12, 5461\u20135470 (2012).","journal-title":"Sensors"},{"key":"53220_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jjco\/hyi253","volume":"36","author":"Z Zhigang","year":"2006","unstructured":"Zhigang, Z. & Wenlv, S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Jpn. J. Clin. Oncol. 36, 121 (2006).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"53220_CR15","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-09-3169","volume":"16","author":"N Saeki","year":"2010","unstructured":"Saeki, N., Gu, J., Yoshida, T. & Wu, X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin. Cancer Res. 16, 3533\u20133538 (2010).","journal-title":"Clin. Cancer Res."},{"key":"53220_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00280-011-1759-9","volume":"69","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis, E. S. et al. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother. Pharmacol. 69, 763\u2013771 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"53220_CR17","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1093\/annonc\/mds078","volume":"23","author":"MJ Morris","year":"2012","unstructured":"Morris, M. J. et al. A phase I\/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann. Oncol. 23, 2714\u20132719 (2012).","journal-title":"Ann. Oncol."},{"key":"53220_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/hum.2013.209","volume":"25","author":"D Abate-Daga","year":"2014","unstructured":"Abate-Daga, D. et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum. Gene Ther. 25, 1003\u20131012 (2014).","journal-title":"Hum. Gene Ther."},{"key":"53220_CR19","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff, T. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 30, 1636\u20131644 (2024).","journal-title":"Nat. Med."},{"key":"53220_CR20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","volume":"19","author":"Z Gu","year":"2000","unstructured":"Gu, Z. et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288\u20131296 (2000).","journal-title":"Oncogene"},{"key":"53220_CR21","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu, S. S. CAR-T efficacy: is conditioning the key? Blood 133, 1799\u20131800 (2019).","journal-title":"Blood"},{"key":"53220_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/00912700122010771","volume":"41","author":"JD Iuliucci","year":"2001","unstructured":"Iuliucci, J. D. et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J. Clin. Pharmacol. 41, 870\u2013879 (2001).","journal-title":"J. Clin. Pharmacol."},{"key":"53220_CR23","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).","journal-title":"Clin. Cancer Res."},{"key":"53220_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.17662","volume":"194","author":"MR Hines","year":"2021","unstructured":"Hines, M. R. et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br. J. Haematol. 194, 701\u2013707 (2021).","journal-title":"Br. J. Haematol."},{"key":"53220_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"53220_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"53220_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"53220_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Themeli, M. & Usmani, S. Z. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2, 302\u2013318 (2021).","journal-title":"Blood Cancer Discov."},{"key":"53220_CR29","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans, R. P. et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate 76, 1257\u20131270 (2016).","journal-title":"Prostate"},{"key":"53220_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","volume":"31","author":"SF Slovin","year":"2013","unstructured":"Slovin, S. F. et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31, 943\u2013949 (2013).","journal-title":"Vaccine"},{"key":"53220_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"53220_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay, K. A. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br. J. Haematol. 183, 364\u2013374 (2018).","journal-title":"Br. J. Haematol."},{"key":"53220_CR33","doi-asserted-by":"crossref","unstructured":"Neelapu, S. S. et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 135, 2106\u20132109 (2020).","DOI":"10.1182\/blood.2019004162"},{"key":"53220_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jgo.2020.07.006","volume":"12","author":"ME Zettler","year":"2021","unstructured":"Zettler, M. E. et al. Real-world adverse events associated with CAR T-cell therapy among adults age \u2265 65 years. J. Geriatr. Oncol. 12, 239\u2013242 (2021).","journal-title":"J. Geriatr. Oncol."},{"key":"53220_CR35","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","volume":"6","author":"VA Fabrizio","year":"2022","unstructured":"Fabrizio, V. A. et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 6, 1961\u20131968 (2022).","journal-title":"Blood Adv."},{"key":"53220_CR36","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama, A. V. et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133, 1876\u20131887 (2019).","journal-title":"Blood"},{"key":"53220_CR37","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.2022.40.16_suppl.2539","volume":"40","author":"MO Butler","year":"2022","unstructured":"Butler, M. O. et al. The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301. J. Clin. Oncol. 40, 2539\u20132539 (2022).","journal-title":"J. Clin. Oncol."},{"key":"53220_CR38","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"53220_CR39","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva, M., Duchateau, P., Depil, S., Poirot, L. & Valton, J. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294, 5430\u20135437 (2019).","journal-title":"J. Biol. Chem."},{"key":"53220_CR40","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","volume":"195","author":"HM Mehta","year":"2015","unstructured":"Mehta, H. M., Malandra, M. & Corey, S. J. G-CSF and GM-CSF in neutropenia. J. Immunol. 195, 1341\u20131349 (2015).","journal-title":"J. Immunol."},{"key":"53220_CR41","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum, U. et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 5, 2799\u20132806 (2021).","journal-title":"Blood Adv."},{"key":"53220_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"53220_CR43","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J. Clin. Oncol. 34, 1402\u20131418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"53220_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53220-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53220-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53220-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T12:03:36Z","timestamp":1735560216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53220-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53220"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53220-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.J., J.S., J.H.B., and C.S. were employees of Bellicum Pharmaceuticals at the time of the study conduct and manuscript preparation. M.S. consulting or advisory role: Merck Sharp & Dohme, Exelixis, Xencor Research, Janssen Oncology, Vaccitech, Bristol-Myers Squibb\/Medarex; research funding: Bellicum Pharmaceuticals, Oncoceutics, Merck Sharp & Dohme, Janseen Oncology, Medivation\/Astellas, Advaxis, Suzhou Kintor Pharmaceuticals, Harpoon, Bristol-Myers Squibb, Genocea Biosciences, Lilly, Nektar, Seattle Genetics, Xencor, Tmunity, Exelixis, Regeneron, Bicycle Therapeutics, AstraZeneca. E.D. research or grant funding: Bayer HealthCare Pharmaceuticals Inc., Immunocore LTD., Amgen, Aileron Therapeutics, Compugen Ltd., TRACON Pharmaceuticals Inc., Unum Therapeutics, Gilead Immunomedics, BOLT Therapeutics, Aprea Therapeutics, Bellicum Pharmaceuticals, PMV Pharma, Triumvira Immunologics, Seagen Inc., Mereo BioPharma 5 Inc., Sanofi, Rain Oncology, Astex Therapeutics, Sotio, Poseida, Mersana Therapeutics, Genentech, Boehringer Ingelheim, Dragonfly Therapeutics. Advisory board: BOLT Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics, PMV Pharma. Speaker: PMV Pharma; travel, accommodations, expenses: ASCO, LFSA Association, Rain Oncology, Banner MD Anderson Cancer Center, Triumvira Immunologics. W.S. has served as a paid consultant (DSMB) for AstraZeneca, Merck, Pfizer, Treadwell Therapeutics; consultant (other): AstraZeneca, Caremark\/CVS, EMA Wellness, Fortress Biotech; Speakers Bureau: CME providers (sponsorship unknown): Dava Oncology, Global Academy for Medical Education, OncLive, PeerView, Research to Practice, Vindico; Grant\/research support (to institution): Abbvie, Amgen, AstraZeneca, Astellas (Medivation), Bayer, Bristol-Myers-Squibb, Boehringer Ingelheim, Calithera, Clovis, Corvus, Eisai, Exilixis, Genentech (Roche), Johnson & Johnson (Janssen), Merck, Novartis, Pfizer, Seattle Genetics, X4Pharmaceuticals, Xencor; Stockholder: Fortress Biotech; Expert Witness: Apotex, DRL, Mylan, Sandoz; Miscellaneous\/Editorial: Cancer (ACS), Up-To-Date, Kidney Cancer Journal. B.A.T. has served as a paid consultant\/advisor to Seagen, Exelixis, Lilly, and Sanofi; grant reviewer for Pfizer; and has received research funding (to his institution) from Bristol-Myers Squibb and Bellicum Pharmaceuticals. R.R. has acted as a consultant for Atara Biotherapeutics, Capstan Therapeutics, Gilead Sciences, Incyte Corporation, Instil Bio, Jasper Therapeutics, Midatech Pharma US Inc., Regeneron Pharmaceuticals, Synthekine, Takeda Oncology, TScan. He has served as an expert witness for Bayer CropScience; Travel has been provided by Gilead and Incyte; Additionally, he serves on the End Point Review Committee for OrcaBio and Data and Safety Monitoring for Perelman School of Medicine, University of Pennsylvania. He holds two US patents for methods for treating graft-versus-host disease (US 83\/139,490 and US 81\/731, 943). M.G.: Speakers\u2019 Bureau\u2014BMS, Lilly, Merck; Advisory board: Sanofi; Consultant: Merck, Celularity, Guardant. He has received research funding from: Acerta Pharma; Adlai Nortye; Arcus Biosciences; Array BioPharma; Bayer; Bellicum Pharmaceuticals; BMS; Boehringer Ingelheim; Celgene; Checkpoint Therapeutics; Compass Therapeutics; Constellation Pharmaceuticals; Cullinan Oncology; Cyteir; Daiichi Sankyo Company; Eisai; EMD Serono; EMD Serono; Erasca, Inc; Fate Therapeutics; Georgetown Univ.; GlaxoSmithKline; GSB Pharma; Hackensack Meridian Health; Imugene; Incyte; Infinity Pharmaceuticals; ITeos Therapeutics; Janssen; Johnson & Johnson; KSQ Therapeutics; MedImmune; Memorial Sloan-Kettering Cancer Center; Merck; Millennium; Mirati Therapeutics; Moderna Therapeutics; NextCure; Nimbus Therapeutics; Pfizer; Pharmacyclics; Rapa Therapeutics; Regeneron; Roche\/Genentech; Sanofi; Seagen; Silenseed; Synlogic; Tesaro; Turning Point Therapeutics; Vedanta Biosciences; VelosBio; Verastem; Vincerx Pharma, Amgen, Agenus, AstraZeneca, Beigene, Zailab. U.G. has participated in Speaker Bureau for Incyte. M.A.B. has acted as a paid consultant for and\/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi and has received grants to his institution from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech\/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, Bellicum and Pfizer for work performed as outside of the current study. C.B., M.C., and S.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10743"}}